Telomeres Length in Israeli Fibrotic ILD Patients

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

December 31, 2027

Conditions
Pulmonary Fibrosis
Interventions
DIAGNOSTIC_TEST

leukocyte telomere length (LTL) will be measured using the Telomere Restriction Fragment (TRF) Analysis method

genomic DNA (2-5 µg) is digested overnight at 37°C with HinfI restriction endonuclease. Fragments are being separated on an agarose gel, transferred to a Hybond N+ membrane. The membrane is being hybridized over night at 50°C with a 5' end-labeled (AACCCT)3 oligonucleotide probe and with ladder probe of 1Kb ladder. Following membrane washes the membrane is exposed to PhosphoImager. The mean telomere length is calculated by the computer program Telotool \[19-20\]. TRF analysis will be conducted at the laboratory of Prof. Yehuda Tzfati at the Hebrew University, which is highly experienced in the field of telomere biology and in telomere length analysis. Blood samples will be taken once from each participant. no genetic sequencing will be performed as part of this study.

Sponsors
All Listed Sponsors
collaborator

Tel Aviv Medical Center

OTHER

collaborator

Israel Society of Pulmonology

UNKNOWN

lead

Barzilai Medical Center

OTHER

NCT06885515 - Telomeres Length in Israeli Fibrotic ILD Patients | Biotech Hunter | Biotech Hunter